Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA)
Status:
Completed
Trial end date:
2020-11-09
Target enrollment:
Participant gender:
Summary
This is a double-blind, placebo-controlled, event-driven randomized withdrawal study to
investigate the efficacy and safety of secukinumab treatment in the Juvenile Idiopathic
Arthritis (JIA) categories of Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related
Arthritis (ERA). The study is divided into 3 parts (plus a post-treatment follow-up period)
consisting of open-label, single-arm active treatment in Treatment Periods 1 and 3 and a
randomized, double-blind, placebo controlled, event-driven withdrawal design in Treatment
Period 2